Head & Neck, Volume 41, Issue S1,Pages: 1-56 October 2019

---

This supplement has been supported by Taiwan Head And Neck Society, under an educational grant sponsored by by Bristol‐Meyers Squibb (Taiwan) Ltd and Ono Pharmaceutical Co., Ltd.
ISSUE INFORMATION – CONTENTS

Issue Information – Contents

Pages: 1-2 | First Published: 01 October 2019

SPECIAL ISSUE

 Open Access

Preface for the special issue of “Immunotherapy for head and neck cancers: Current landscapes, emerging biomarkers, and future directions”

Pei‐Jen Lou MD, PhD

Pages: 3 | First Published: 01 October 2019

 Open Access

Immune checkpoint inhibitors for head and neck squamous cell carcinoma: Current landscape and future directions

Hsiang‐Fong Kao MD, Pei‐Jen Lou MD, PhD

Pages: 4-18 | First Published: 01 October 2019

 Open Access

Review of emerging biomarkers in head and neck squamous cell carcinoma in the era of immunotherapy and targeted therapy

Jason Chia‐Hsun Hsieh MD, PhD, Hung‐Ming Wang MD, Min‐Hsien Wu PhD, Kai‐Ping Chang MD, PhD, Pei‐Hung Chang MD, Chun‐Ta Liao MD, Chi‐Ting Liau MD

Pages: 19-45 | First Published: 01 October 2019

 Open Access

Novel immune‐modulating drugs for advanced head and neck cancer

Tien‐Hua Chen MD, Peter M. ‐H. Chang MD, PhD, Muh‐Hwa Yang MD, PhD

Pages: 46-56 | First Published: 01 October 2019